MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$26,727K
Free Cash flow
-$34,411K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds related to common stock...
Change in the estimated fair val...
Proceeds from maturities of mark...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Other non-cash items, net
Purchases of property and equipm...
Accounts payable
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-63,635
-47,210
-58,825
-42,152
Depreciation
2,234
2,391
3,053
3,191
Stock-based compensation expense
5,342
5,662
6,337
5,476
Change in the estimated fair value of contingent consideration
16,362
10,745
8,577
-1,991
Change in the estimated fair value of success payment liabilities
7,551
-2,312
5,512
5,115
Non-cash expense for operating lease right-of-use assets
490
2,468
2,391
2,317
Impairment of long-lived assets
0
-
0
0
Other non-cash items, net
2,256
2,615
3,100
2,082
Prepaid expenses and other assets
-295
-1,628
696
-1,121
Operating lease right-of-use assets and liabilities
-556
1,496
1,458
1,458
Accounts payable
-851
454
-189
-357
Accrued expenses and other liabilities
1,122
-7,094
5,757
1,391
Net cash used in operating activities
-32,790
-37,379
-32,641
-29,429
Purchases of marketable securities
101,672
5,588
36,084
49,527
Proceeds from maturities of marketable securities
15,751
55,065
19,800
1,407
Purchases of property and equipment
1,621
288
873
41
Proceeds from disposal of assets
23
248
661
136
Net cash provided by (used in) investing activities
-87,519
49,437
-16,496
-48,025
Proceeds from employee stock purchase plan and exercise of stock options
245
59
1,059
157
Proceeds related to common stock financings, net
89,646
-
16,680
109,470
Fees related to common stock financings, net
-
96
-
-
Proceeds from issuance of common stock allocated to stock purchase option
3,688
-
-
-
Proceeds (principal payments), net for tenant improvement loan
-
-
-89
-87
Principal payments, net for tenant improvement loan
93
91
-
-
Net cash provided by financing activities
93,582
-128
17,650
109,540
Net decrease in cash, cash equivalents, and restricted cash
-26,727
11,930
-31,487
32,086
Cash, cash equivalents, and restricted cash at beginning of period
87,995
76,065
107,552
131,398
Cash, cash equivalents, and restricted cash at end of period
61,268
87,995
76,065
107,552
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds related to
common stock...
$89,646K
(35193.70%↑ Y/Y)
Proceeds from issuance of
common stock allocated...
$3,688K
Proceeds from employee
stock purchase plan...
$245K
(-83.22%↓ Y/Y)
Net cash provided by
financing activities
$93,582K
(5964.94%↑ Y/Y)
Net decrease in
cash, cash...
-$26,727K
(52.22%↑ Y/Y)
Canceled cashflow
$93,582K
Proceeds from maturities
of marketable...
$15,751K
(-37.88%↓ Y/Y)
Proceeds from disposal of
assets
$23K
(-96.38%↓ Y/Y)
Change in the estimated
fair value of...
$16,362K
(100.42%↑ Y/Y)
Change in the estimated
fair value of success...
$7,551K
(86.21%↑ Y/Y)
Stock-based compensation
expense
$5,342K
(-60.87%↓ Y/Y)
Depreciation
$2,234K
(-65.66%↓ Y/Y)
Accrued expenses and
other liabilities
$1,122K
(109.44%↑ Y/Y)
Operating lease
right-of-use assets and...
-$556K
(-786.42%↓ Y/Y)
Non-cash expense for
operating lease...
$490K
(-89.02%↓ Y/Y)
Prepaid expenses and
other assets
-$295K
(60.14%↑ Y/Y)
Net cash provided by
(used in) investing...
-$87,519K
(-460.41%↓ Y/Y)
Canceled cashflow
$15,774K
Net cash used in
operating activities
-$32,790K
(59.89%↑ Y/Y)
Canceled cashflow
$33,952K
Purchases of marketable
securities
$101,672K
(5944.71%↑ Y/Y)
Purchases of property and
equipment
$1,621K
(6654.17%↑ Y/Y)
Net loss
-$63,635K
(55.56%↑ Y/Y)
Other non-cash items,
net
$2,256K
(-61.06%↓ Y/Y)
Accounts payable
-$851K
(71.62%↑ Y/Y)
Buy us a coffee
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)